See what's new before you renew your PT/EQA for 2026

We anticipate your PT/EQA needs because laboratory quality drives everything we do. Our PT/EQA programs follow the updated CMS participation requirements so you can continue to deliver accurate and reliable results.

Highlights

  • H5N1 Influenza A Detection and Subtyping program for US laboratories (FLUA)
  • Global program for Dengue Virus Serology (DENS)
  • PT/EQA program for Optical Genome Mapping (OGM)
  • Verification of analytical measurement range with new linearity test covering reticulocytes (LN53)

View all our new programs and decide which ones are right for you.

New PT/EQA Programs for 2025/2026

  • Open all Toggle
  • Close all Toggle
  • Preparation of histologic slides in pathology laboratories with a pediatric caseload (HQPED)
  • PT/EQA program for Human Papillomavirus (High Risk) for Cytopathology (CHPV)
  • Immunohistochemistry Interpretation-only programs for Gastric, Pan Tumor HER2 (GPH/GPH1), HER2 and ER (HERI/HERI1), PD-L1 Tumor Proportion Score IHC (TPS/TPS1)
  • PT/EQA program exclusively for measuring parathyroid hormone levels (PTH)
  •  PT/EQA program for Point-of-Care High-Sensitivity Troponin I (PCHT)
  • Waived Hematocrit, Hemoglobin, and Urinalysis/Urine hCG (HCC3) plus waived Whole Blood Glucose (HCC4)
  • PT/EQA program for Optimal Genome Mapping (OGM)
  • HLA antibody screen only (MXS) or with crossmatching, identification, and extra plasma (MXEP)
  •  PT/EQA program for Thyroid Stimulating Hormone Receptor Binding Antibody (TSHR)
  • Gastrointestinal panel created specifically for laboratories outside the US (GIPN)
  • CLIA-compliant five-challenge PT/EQA programs for rapid malaria (RML5) and Trichomonas vaginalis, molecular (TVG5)
  • PT/EQA program for H5N1 Influenza A Detection and Subtyping for US laboratories (FLUA)*
  • Global PT/EQA program for Dengue Virus Serology (DENS)
  • HIV-1/HIV-2 Detection and Differentiation, Molecular program (HVDD)
  • PT/EQA program Shiga Toxin, extra volume (STX)*

* This program is only available to customers within the US.

  • New PT/EQA offerings for automated (JATXM) and comprehensive methods (JXM) with electronic crossmatch
  • PT/EQA program for Weak RHD Genotyping (WRHG)
  • Red Blood Cell Antigen Typing—Automated program (ARCT)
  • Viral marker for Nucleic Acid Testing, Babesia (NAT1)

New Quality Improvement Programs for 2025/2026

  • Open all Toggle
  • Close all Toggle
  • Calibration verification and linearity covering Factor VIII (LN51), Hepatitis B viral load (LN52), cystatin C (LN49), and a comprehensive panel of thyroid analytes (LN50)
  • Reticulocyte Calibration Verification/Linearity (LN53)

Performance monitors and comparability assessment across multiple instruments for:

  • High-sensitivity cardiac markers (HCRQ)
  • Critical care blood gas with hematocrit and estimated hemoglobin (AQHQ)
  • Critical care blood gas using an i-STAT instrument (AQSQ)

Aid quality improvement efforts and assist checklist requirements in your laboratory with:

  •  Comparative Inpatient Analyte Volumes for Individual and Integrated Laboratories (QPA5/QPA10)

New Continuing Medical Education Programs

Advance skills with educational activities developed by physicians and doctoral scientists with expertise in pathology and laboratory medicine.

  • Discernment of potential discrepancies between biomarker testing modalities for individual (NMBA) and additional participant(s) (NMB1)

New CAP Publications for 2026

Stay current in diagnostic learning with our newest high-quality publications written and edited by recognized experts in pathology and laboratory medicine.